Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib + Fulvestrant + Eribulin in T-DXd Resistant HR+/HER2+ Advanced Breast Cancer
NCT07333937Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by Xijing Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07333937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333937.